Reblozyl Side Effects
Generic name: luspatercept
Medically reviewed by Drugs.com. Last updated on Sep 21, 2024.
Note: This document provides detailed information about Reblozyl.
Applies to luspatercept: parenteral injection for sub-q use Side Effects associated with luspatercept. Some dosage forms listed on this page may not apply specifically to the brand name Reblozyl.
Applies to luspatercept: parenteral injection for sub-q use.
Side effects include:
Most common (>10%) adverse reactions: fatigue, headache, musculoskeletal pain, arthralgia, dizziness/vertigo, nausea, diarrhea, cough, abdominal pain, dyspnea, COVID-19, peripheral edema, hypertension, hypersensitivity.
For healthcare professionals
Applies to luspatercept: subcutaneous powder for injection.
Hepatic adverse events
- Very common (10% or more): Total bilirubin 2 or more times the upper limit of normal (ULN) (64%), alanine aminotransferase 3 or more times ULN (12%), aspartate aminotransferase 3 or more times ULN (11%)
- Common (1% to 10%): Alkaline phosphatase 2 or more times ULN, direct bilirubin 2 or more times ULN[Ref]
Cardiovascular
- Common (1% to 10%): Hypertension, deep vein thrombosis[Ref]
Nervous system
- Very common (10% or more): Headache (26%), dizziness (11%)
- Common (1% to 10%): Cerebrovascular accident[Ref]
Musculoskeletal
- Very common (10% or more): Bone pain (20%), arthralgia (19%)[Ref]
Gastrointestinal
- Very common (10% or more): Abdominal pain (14%), diarrhea (12%)
- Common (1% to 10%): Nausea[Ref]
Metabolic
- Common (1% to 10%): Hyperuricemia[Ref]
Respiratory
- Very common (10% or more): Cough (14%)[Ref]
Immunologic
Other
- Very common (10% or more): Fatigue (14%)
- Frequency not reported: Death (due to unconfirmed acute myelogenous leukemia)[Ref]
See also:
References
1. (2019) "Product Information. Reblozyl (luspatercept)." Celgene Corporation
More about Reblozyl (luspatercept)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous erythropoiesis agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Reblozyl side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
